BIIB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIIB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Biogen's Goodwill for the quarter that ended in Sep. 2024 was $6,486 Mil. Biogen's Total Assets for the quarter that ended in Sep. 2024 was $28,313 Mil. Therefore, Biogen's Goodwill to Asset Ratio for the quarter that ended in Sep. 2024 was 0.23.
The historical data trend for Biogen's Goodwill-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Goodwill-to-Asset | Get a 7-Day Free Trial | 0.21 | 0.23 | 0.24 | 0.23 | 0.23 |
Biogen Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Goodwill-to-Asset | Get a 7-Day Free Trial | 0.24 | 0.23 | 0.23 | 0.23 | 0.23 |
For the Drug Manufacturers - General subindustry, Biogen's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Biogen's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where Biogen's Goodwill-to-Asset falls into.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
Biogen's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Goodwill to Asset (A: Dec. 2023 ) | = | Goodwill | / | Total Assets |
= | 6219.2 | / | 26844.8 | |
= | 0.23 |
Biogen's Goodwill to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as
Goodwill to Asset (Q: Sep. 2024 ) | = | Goodwill | / | Total Assets |
= | 6485.8 | / | 28313.2 | |
= | 0.23 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (NAS:BIIB) Goodwill-to-Asset Explanation
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Thank you for viewing the detailed overview of Biogen's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Priya Singhal | officer: Head of Development | C/O ZAFGEN, INC., 175 PORTLAND STREET 4TH FL, BOSTON MA 02114 |
Eric K Rowinsky | director | IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014 |
Jane Grogan | officer: Head of Research | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Susan Langer | director | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Ginger Gregory | officer: EVP, Human Resources | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Adam Keeney | officer: Head of Corporate Development | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Christopher Viehbacher | director, officer: President and CEO | C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Susan H Alexander | officer: EVP, General Counsel | C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Nicole Murphy | officer: Head of Pharm Ops and Tech | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Rachid Izzar | officer: Head of Alzheimer's Disease | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Alfred Sandrock | officer: Grp SVP, Chief Medical Officer | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Chirfi Guindo | officer: EVP Glob. Mkt Acc & Cust Innov | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Brian S Posner | director | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Jones William D /ca/ | director | |
Maria C Freire | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
From GuruFocus
By Marketwired • 10-22-2024
By GuruFocus News • 10-30-2024
By GuruFocus News • 11-05-2024
By GlobeNewswire • 10-27-2024
By Marketwired • 11-19-2024
By GuruFocus News • 12-03-2024
By Marketwired • 09-12-2024
By GuruFocus News • 10-31-2024
By Marketwired • 10-09-2024
By GuruFocus News • 10-16-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.